In the news
Sep 8, 2025

A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria
Biopharma Dive
Sep 8, 2025
Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson's and ALS
Biotech TV
Sep 8, 2025

A British mitochondrial startup wants to break ground in ALS and Parkinson's. It has £50M to try
Endpoints News
Mar 8, 2025

Mitochondria: Movers and Shakers - a podcast about life with Parkinson's
Apple Podcasts
Oct 31, 2024

NRG Therapeutics launches Series B after $5m boost from Michael J. Fox Foundation
Business Weekly
Sep 13, 2024

NRG Therapeutics gets grant to test mitochondria-targeting ALS therapy
ALS News Today
Feb 22, 2023

MJFF grant supports NRG Therapeutics' work to validate mitochondrial drug target for Parkinson's
Bioworld
Dec 7, 2022

Parkinson’s disease drug hunters think outside the α-synuclein box
Nature Biotechnology
Nov 10, 2022

NRG raises Series A funds for Parkinson’s and ALS therapy development
Pharmaceutical Technology
Nov 10, 2022

Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS
Labiotech
Nov 9, 2022

NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson's, ALS
Biospace
Nov 9, 2022

NRG closes £16M series A to fund fight against neurodegenerative diseases
Bioworld
Nov 9, 2022

GSK vets theorize that a mitochondrial target may unlock Parkinson's and ALS treatments in new startup
Endpoints
Jul 7, 2022

NRG Therapeutics and Domainex to collaborate on discovery of small molecules to treat Parkinson’s or motor neurone disease
Cambridge Independent
Jul 1, 2022

NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
PMLive